Systematic review / meta-analysis / 2006
Combining Astragalus-based Chinese herbal medicine with platinum chemotherapy was associated with reduced 12-month mortality and improved tumor response in NSCLC.
A meta-analysis evaluated 34 randomized trials including 2,815 patients with advanced non-small-cell lung cancer to assess Astragalus-based Chinese herbal medicine combined with platinum-based chemotherapy versus chemotherapy alone. Twelve studies (n = 940) reported a reduced risk of death at 12 months (RR = 0.67; 95% CI, 0.52 to 0.87), and 30 studies (n = 2,472) reported improved tumor response (RR = 1.34; 95% CI, 1.24 to 1.46). In subgroups, Jin Fu Kang reduced death at 24 months (RR = 0.58; 95% CI, 0.49 to 0.68), and Ai Di injection stabilized or improved Karnofsky performance status (RR = 1.28; 95% CI, 1.12 to 1.46). Authors noted results require confirmation with rigorously controlled trials.
- Study type
- Systematic review and meta-analysis of randomized trials
- Who was studied
- 2,815 patients with advanced non-small-cell lung cancer across 34 randomized studies
- What was measured
- Survival (risk of death), tumor response, Karnofsky performance status, and chemotherapy toxicity
THE PAPER
Astragalus-based Chinese herbs and platinum-based chemotherapy for advanced non-small-cell lung cancer: meta-analysis of randomized trials.
McCulloch M, See C, Shu XJ, Broffman M, Kramer A, Fan WY, Gao J, Lieb W, Shieh K, Colford JM. J Clin Oncol, 2006.
This note is written from the study's published abstract. It summarizes what the authors reported; it is not medical advice and does not replace reading the full paper.